An interventional study of Indwelling Catheter and Intermittent Catheterization in Urogenital, Urinary Tract Infections and Hip Fractures, sponsored by Ottawa Hospital Research Institute. Status unknown at 1 site in Canada. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2022-05-02.
Sponsored by Ottawa Hospital Research Institute · Not applicable, Interventional, and Other
The primary aim of the proposed pilot feasibility is to determine whether it is feasible to recruit patients with a hip fracture into a prospective study and randomize them to either indwelling or intermittent catheterization. The study hypothesis is that the investigators would be able to show that this study can be incorporated into clinical practice, with satisfactory rate of patient recruitment and retention. Thus, the investigators would be able to compete this pilot study trial and proceed towards a multi-center trial.
The primary aim of the proposed pilot feasibility is to determine whether it is feasible to recruit patients with a hip fracture into a prospective study and randomize them to either indwelling or intermittent catheterization.
The study hypothesis is that the investigators would be able to show that this study can be incorporated into clinical practice, with satisfactory rate of patient recruitment and retention. Thus, the investigators would be able to compete this vanguard trial and proceed towards a multi-center trial.
Secondary objectives would be related to safety and patient activity that would be important endpoints for the definitive, large scale trial. These would include the following:
Eligible patients will be approached for consent at admission and, if willing to participate, will be randomized into Group A or Group B using a web-based, computer-generated randomization with permuted blocks of varying sizes.
Data Collection will include:
A clinical research coordinator (CRC) will oversee study recruitment and assess number of study participants to the total number of patients admitted with a hip fracture which will allow for documentation of ability to recruit into the study. Furthermore, the CRC will prospectively record each patent's journey to assess whether enrolled patients are receiving the treatment they are randomized to. All enrolled patients will be asked to fill in a patient satisfaction score that has been in use already at our institution.
A CRC, blinded to the arm patients were randomized to, will be responsible for recording all outcome measures of interest prospectively in the study's database from the participant's electronic medical records. Validity of data extraction will be tested for a randomly selected 10% of the cohort by a second evaluator (CRC not previously involved in the study).
Data analyses will include:
Descriptive Statistics: Given the feasibility purpose of the vanguard trial, descriptive statistics will be used to summarize demographics and baseline prognostic factors of participants allocated to the two trial arms.
Analysis of Primary Outcome: Our primary endpoint is the rate of enrolment to ensure the ability to undertake a larger multi-centered trial. An average rate of 10 patients/month or greater will be considered as ideal for establishing feasibility. An enrollment of less than 5 patients/month will likely jeopardize the ability to feasibly recruit for the larger trial. Whereas, average monthly enrolment of 5 to 10 patients will require a re-evaluation of our recruitment strategy, intervention specifications, and/or eligibility criteria to improve enrolment.
Analysis of Secondary Outcomes: Given the vanguard nature of this trial, the investigators will not undertake inferential analyses of our secondary outcomes but rather these patients will be carried forward into the larger trial.
753 studies on the registry are indexed under Urinary Tract Infections; 128 are open to participants now.
This study's planned enrollment of 120 is close to the median of 130 across 524 interventional studies indexed under Urinary Tract Infections.
Browse Urinary Tract Infections studies →Ottawa Hospital Research Institute is the lead sponsor of 538 studies on the registry; 100 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Foley catheterization upon admission and removed the morning following surgery.
Device: Indwelling Catheter
Intermittent catheterization when post-void residual volume is greater than 400 mL.
Device: Intermittent Catheterization
Patients in the experimental group will receive foley catheter upon admission, aseptically. The catheter will be discontinued on the morning following surgery. At TOH most (\>75%) hip fractures are treated within 48 hours of admission and 95% within 72 hours and hence the indwelling catheter is likely to stay in place for 3-4 days.
Patients randomized to the intermittent catheterization group will have their PVR monitored every 8 hours pre-operatively. If PVR\>400 mL, an intermittent catheter will be used. If PVR\> 400 mL greater than 3 times pre-operatively, an indwelling catheter will be placed the fourth time. The indwelling catheter will be removed the morning of post-op day 1. It is expected that a small percentage of patients in either group will not have a PVR\>400 mL preoperatively. These patients will not be catheterized but will remain in the study. Post-operatively, both treatment groups will have their PVR monitored for 24 hours, or until PVR is less than 200 mL. If PVR\>400 mL and the patient is not able to void further, intermittent catheterization will be done every six hours as needed. If post-operative PVR\>400 mL greater than 3 times post-operatively, an indwelling catheter will be placed the fourth time.
Study Feasibility - Enrollment
Number of participants enrolled and willingness of participants to be randomized Comparing the Number of patients screened compared to the number of patients meeting eligibility criteria. Tracking crossover between the treatment groups, participant retention, and follow-up rates.
Time frame: One year
Study Feasibility - Screening
Number of patients screened and number meeting eligibility
Time frame: One year
Study Feasibility - Retention
Participant retention rate in study
Time frame: One year
Study Feasibility - Follow-up
Rates of participant follow-up
Time frame: One year
Safety-Related Outcomes - Rates of UTI
Number of patients who present with a post-operative UTI within 30 days of catheterization
Time frame: 30 days
Safety-Related Outcomes - Rates of POUR
Number of patients who present with post-operative POUR within 30 days of catheterization
Time frame: 30 days
patient experience questionnaire
the patient experience questionnaire, created by the principal investigator of the study, will be used to assess patients level of urogenital pain and discomfort and satisfaction with catheterization.
Time frame: pre-operatively, and post-operative day six or at discharge
Plan to share: No
This study is status unknown, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Ottawa Hospital Research Institute